Plain-English translation of NCT03325556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied pimavanserin, a medication designed to help prevent psychotic symptoms (like hallucinations and delusions) from returning in people with dementia. Participants who had responded well to 12 weeks of open-label treatment with pimavanserin then received either the medication or a placebo to see whether the treatment could keep their symptoms from coming back.
Hallucinations and delusions in dementia patients can be distressing and dangerous, but treatments are limited. This trial was designed to find out whether continuing this medication after an initial improvement could help prevent these symptoms from recurring.
After successfully responding to 12 weeks of open-label pimavanserin treatment, participants were randomly assigned to receive either the medication or a placebo for a relapse prevention phase. Throughout the study, participants attended regular visits where their psychotic symptoms were monitored to see whether the medication prevented symptoms from returning compared to placebo.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States